정부/공공기관
임상시험센터
CRO
분석CRO/센트럴랩
유관기관/협회
정보서비스
해외 유관 기관
* CRO 게재 기준: CRO자율등록 기관
ClinicalTrials.gov에 등록된 정보를 기준으로 코로나-19(COVID-19) 관련 글로벌 임상시험 현황을 제공합니다.
전체 2550건이 검색되었습니다.
| No. | Status | Study Title | Conditions | Interventions | Phase | Sponsor/Collaborators | Funder Type | Number Enrolled | Sex | Age | Locations |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 219 | Not yet recruiting | The Safety and Efficacy of SCTA01 Against COVID-19 in Patients Admitted to High Dependence or Intensive Care | Covid19 | Biological: SCTA01 Biological: SCTA01 Placebo |
Phase 3 | Sinocelltech Ltd. | INDUSTRY | 560 | All | 18 Years | |
| 218 | Not yet recruiting | The Safety and Efficacy of SCTV01C in Population Aged ≥18 Years Previously Vaccinated With Inactivated COVID-19 Vaccine.Healthy Population Aged ≥18 Years Previously Vaccinated With Adenovirus Vectored or mRNA COVID-19 Vaccine. | SARS-CoV-2 Infection | Biological: SCTV01C Other: Placebo |
Phase 3 | Sinocelltech Ltd. | INDUSTRY | 12420 | All | 18 Years | |
| 217 | Not yet recruiting | The Safety and Immunogenicity of a DNA-based Vaccine (COVIGEN) in Healthy Volunteers | SARS-CoV2 COVID-19 | Biological: COVIGEN 0.8 mg ID or Placebo ID Biological: COVIGEN 2.0 mg IM or Placebo IM Biological: COVIGEN 4.0 mg IM or Placebo IM |
Phase 1 | University of Sydney, Bionet Co., Ltd, Technovalia, Telethon Kids Institute, Institute for Clinical Pathology and Medical Research | OTHER | 150 | All | 18 Years ~ 75 Years | Scientia Clinical Research, Randwick, New South Wales, Australia Vaccinology and Immunology Research Trials Unit, Women's and Children's Hospital, Adelaide, South Australia, Australia Wesfarmers Centre of Vaccines and Infectious Diseases Telethon Kids Institute, Perth, Western Australia, Australia |
| 216 | Recruiting | The Safety and Preliminary Tolerability of Lyophilized Lucinactant in Adults With Coronavirus Disease 2019 (COVID-19) | Acute Lung Injury/Acute Respiratory Distress Syndrome (ARDS) | Drug: Lucinactant | Phase 2 | Windtree Therapeutics | INDUSTRY | 20 | All | 18 Years ~ 75 Years | University California San Diego - Jacobs Medical Center, La Jolla, California, United States University of California San Diego - Medical Center, Hillcrest, San Diego, California, United States Augusta University Health, Augusta, Georgia, United States University of Kentucky, Lexington, Kentucky, United States Tufts Medical Center, Boston, Massachusetts, United States Brigham and Womens, Boston, Massachusetts, United States Duke University Medical Center, Durham, North Carolina, United States CEMIC - Centro de Educacion Medica e Investigaciones Clinicals, Buenos Aires, Argentina Hospital Aleman, Buenos Aires, Argentina Hospital Italiano, Buenos Aires, Argentina Sanatorio Guemes, Buenos Aires, Argentina |
| 215 | Recruiting | The Safety of Administering a Second Dose of a COVID-19 mRNA Vaccine in Individuals Who Experienced a Systemic Allergic Reaction to an Initial Dose | Systemic Allergic Reaction | Biological: Pfizer-BioNTech COVID-19 Vaccine (comirnaty) Other: Placebo |
Phase 2 | National Institute of Allergy and Infectious Diseases (NIAID) | NIH | 100 | All | 18 Years ~ 69 Years | National Institutes of Health Clinical Center, Bethesda, Maryland, United States |
| 214 | Recruiting | The Safety of Molnupiravir (EIDD-2801) and Its Effect on Viral Shedding of SARS-CoV-2 (END-COVID) | SARS-CoV 2 | Drug: EIDD-2801 Drug: Placebo |
Phase 2 | Ridgeback Biotherapeutics, LP | INDUSTRY | 96 | All | 18 Years | Ronald Reagan UCLA Medical Center, Los Angeles, California, United States Cook County Hospital, Chicago, Illinois, United States Advocate Christ Medical Center, Oak Lawn, Illinois, United States Advocate Lutheran General Hospital, Park Ridge, Illinois, United States Ochsner LSU Health Shreveport Academic Medical Center, Shreveport, Louisiana, United States Johns Hopkins Bayview Medical Center, Baltimore, Maryland, United States John Hopkins Hospital, Baltimore, Maryland, United States Suburban Hospital, Bethesda, Maryland, United States Howard County General Hospital, Columbia, Maryland, United States Wake Forest Baptist Health, Winston-Salem, North Carolina, United States Vanderbilt University, Nashville, Tennessee, United States Houston Methodist Hospital, Houston, Texas, United States |
| 213 | Completed | The Safety, Tolerability, and Pharmacokinetics of Inhaled TLC19 in Healthy Volunteers | COVID-19 | Drug: TLC19 Drug: TLC19 Vehicle |
Phase 1 | Taiwan Liposome Company | INDUSTRY | 30 | All | 18 Years ~ 65 Years | Mackay Memorial Hospital Tamsui Branch, Taipei, Taiwan |